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Abstract- In this study, our aim was to produce a generation of GMP-grade adipose tissue-derived 
mesenchymal stem cells for clinical applications. According to our results, we fulfill to establish consistent and 
also reproducible current good manufacturing practice (cGMP) compliant adipose tissue-derived mesenchymal 
stem cells from five female donors. The isolated cells were cultured in DMEM supplemented with 10% fetal 
bovine serum and characterized by standard methods. Moreover, karyotyping was performed to evaluate 
chromosomal stability. Mean of donors’ age was 47.6 ± 8.29 year, mean of cell viability was 95.6 ± 1.51%, and 
cell count was between 9×106 and 14×106 per microliter with the mean of 12.2×106 ± 2863564.21 per 
microliter. The main aim of this project was demonstrating the feasibility of cGMP-compliant and clinical grade 
adipose tissue-derived mesenchymal stem cells preparation and banking for clinical cell transplantation trials. 
© 2015 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2015;53(9):540-546.  
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Introduction 
 
Stem cells which can be derived from different 
sources demonstrate promising therapeutic evidences for 
cellular therapies (1). On the other hand, cellular therapy 
as an interesting area in biological sciences have grown 
dramatically (2,3). Among different types of stem cells, 
mesenchymal stem cells (MSCs) have increasingly used 
for cell therapy trials. MSCs are -multipotent cells with 
the ability to differentiate into mesoderm derived cells- 
can be isolated from almost all tissues for instance; bone 
marrow, umbilical cord tissue and blood, adipose tissue, 
dental pulp, synovial membrane and fluid, skin, etc. 
(4,5). Furthermore, they have some proven 
immunomodulatory, hematopoiesis, and regeneration 
capabilities that have led their utilization in clinical cell 
transplantation trials (1,6). Although bone marrow is the 
most common source for MSCs, the number of bone 
marrow-derived MSCs and their differentiation potential 
dramatically decrease with age (only 0.002% of total 
stromal cell population). In addition, the isolation of 
MSCs from bone marrow is an invasive and painful 
procedure. Therefore, scientists tried to find and develop 
an alternative source of MSCs. Human subcutaneous 
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adipose tissue provides an easy and repeatable access to 
adipose tissue while the simple isolation procedures 
provide a clear advantage (1,7). Therefore, adipose 
tissue-derived stromal cells (ASCs) seem as a superior 
choice for cellular therapy because of several advantages 
such as a large number of isolated cells using a 
minimally invasive procedure (8). Furthermore, various 
basic, experimental, and clinical researches have 
revealed the enormous potential of ASCs in regenerative 
medicine (9-16). Significantly, increasing clinical 
transplantation of ASCs has shown the importance of 
several concerns regarding the clinical application of 
these cells and also has been accompanied by the 
regulations governing cellular therapies (2). In spite of 
the great hope and opportunity that have provided by 
stem cell therapy (using ASCs or other types of stem 
cells), there are some considerable risks (17). These 
risks can be divided into intrinsic and extrinsic factors. 
Intrinsic factors result from cell characteristics such as 
differentiation status, tumorigenic potential, 
proliferation capacity, life span, viability, etc. On the 
other hand, extrinsic factors as raw materials, 
manufacturing processes, storage and transportation 
condition, etc. are also important in all cellular therapy 
projects (17). Accordingly, it is recommended that the 
clinical grade preparation of stem cells (e.g., ASCs, 
bone marrow-MSCs) should be performed in accordance 
with current good manufacturing practice (cGMP) 
guidelines that are used for facility or manufacture, 
processing, packing controls (18,19) to overcome most 
of the extrinsic and some of the intrinsic risk factors, and 
ensure the safety, quality, characteristics, and identity of 
cell products (20-22). Additionally, cell manufacturing 
in accordance with GMP standards involves several 
issues similar to drugs manufacturing guidelines (6).  
 
GMP-compliant cellular therapy 
Bridging between stem cell basic science and clinical 
practice is one of the most complex organizational and 
regulatory areas (23). Consequently, advanced cellular 
therapy requires extensive validation, process control, 
and documentation and clearly speculates the critical 
importance of production methods, as well as the 
potential risks (2). Therefore, implementation of a 
quality management system in accordance with 
international standards such as GMP can greatly reduce 
these risks (24). The Food and Drug Administration 
(FDA) has defined human cells, tissues, cellular and 
tissue-based products (HCT/Ps), in two categories; the 
lower risk category or “minimally manipulated” 
products and the higher-risk category or “more than 
minimally manipulated” products. Accordingly, 
manufacturing the first ones must comply with good 
tissue practice (GTP) regulations as a level of control 
similar to that already practiced by most clinical 
laboratories and the second ones must be complied with 
both GTP and GMP (2,25). As we described previously 
we established a clean room facility as the most tangible 
aspect of cGMP, affiliated to brain and spinal injury 
research center to perform (stem) cell transplantation 
trials according to GMP standards (24,26). Our purpose 
in this study was demonstrating the feasibility of GMP-
complaint and clinical grade ASCs manufactured for 
clinical cell therapy trials. 
 
Materials and Methods 
 
After obtaining informed consent, subcutaneous 
adipose tissues from five female donors were harvested 
under aseptic and sterile condition. Harvested tissues 
were placed in tissue container with wet ice and 
transferred to GMP facility.   
 
Tissue digestion and cell isolation 
All isolation and culture procedures were 
accomplished in the GMP facility (clean room) under 
laminar air flow cabinet and according to cGMP 
guidelines. Before processing, samples from tissue and 
transfer medium were sent to a reference laboratory to 
check probable microbiological contamination. Also 
during cell culture period, quality control and 
microbiological tests were repeated to recognize 
probable contamination during manipulation. Then, 
isolated adipose tissues were washed twice with 
phosphate-buffered saline (PBS; CliniMACS®, Miltenyi 
Biotec, Germany) to remove extra blood, small vessels, 
and connective tissues. Subsequently, cleaned adipose 
tissues were cut into very small pieces and were put into 
two or three 50 ml falcon tubes. Then 3 mg/ml 
collagenase-NB6 (GMP-grade, Serva Electrophoresis 
GmbH, Germany) was added to each falcon tube which 
was followed by incubation at 37 °C for 30 minutes. The 
digestion process was stopped by adding an equal 
volume of PBS and the samples were centrifuged at 
600g for 15 minutes at room temperature. The Mature 
adipocytes, debris, and liquid portion were discarded, 
and the stromal vascular fraction (SVF) was 
precipitated. SVF resuspended in PBS was filtered 
through a nylon mesh. Next, the filtered suspension was 
centrifuged at 400g for 10 minutes at 20-C and then was 
transferred to culture flasks. 
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ASCs culture and subcultures 
Approximately 50×103 mixed SVF cells per cm2 
were transferred to each culture flask. Then DMEM 
supplemented with 10% fetal bovine serum (FBS; Pharma 
grade, Australian origin, and gamma irradiated, PAA, 
Austria) were added to each culture flask and placed into 
the incubator under the condition of 37°C, 5% CO2 and 
humidified air. After 48 hours incubation, the cells were 
washed to remove the culture medium, and non-adherent 
cells and the culture medium were renewed by fresh 
medium and every 72 hours the culture medium were 
renewed. At 85–90% confluence, the adipose-derived 
mesenchymal stem cells (ASCs) were harvested by 
enzymatic method and the cells were subcultured while 
cell count number, cell viability, and purity were 
evaluated by Trypan blue (Invitrogen, USA) and 
hemocytometer. ASCs at 3rd subculture were checked for 
chromosomal stability using the karyotyping method.  
 
Characterization of ASCs 
Flow cytometry  
ASCs surface markers were analyzed using flow 
cytometry. Briefly, 1×10 5 cultured ASCs at 3rd 
subculture resuspended in FACS-buffer (3% BSA in 
PBS) and then appropriate fluorescein isothiocyanate 
(FITC) conjugated primary antibodies for 60 minutes at 
4°C. CD44, 11b, 19, 34, 45, 105, 73, and HLA-DR; (all 
from Abcam, USA) were used and afterward, labeled 
ASCs were analyzed on a fluorescence-activated cell 
sorter (FACS; Partec, Denmark).  
 
Differentiation potential  
Adipogenic differentiation: Cultured ASCs incubated 
in adipogenic medium (DMEM supplemented with 50 
µg/ml indomethacin, 10 -7 M dexamethasone, and 50 
µg/ml ascorbate-sodium 2-phosphate (all from Sigma-
Aldrich) for 25 days and each 72 hours culture medium 
was renewed. Then, ASCs were fixed by ethanol for 10 
minutes and stained with oil red O. 
Osteogenic differentiation: ASCs were incubated in 
osteogenic medium (DMEM with 10 mM ß–glycerol 
phosphate, 50µg/ml ascorbate sodium 2-phosphate, and 
10-7 M dexamethasone, 1% antibiotic/antimycotic (all 
from Sigma-Aldrich) for 25 days. Afterward, cell 
fixation was done using ethanol for 10 minutes and 
staining using alizarin red. 
 
Results 
 
Demographic characteristics of adipose tissue donors 
are showed in Table 1. The mean of donors’ age was 
47.6 ± 8.29 year. Also, mean of cell viability was 95.6% 
± 1.51 and about cell count (mean=12.2×106 ± 
2863564.21 per microliter). Mean of tissue weight was 
17.14 ± 1.99 gr. Cell processing time was ranged from 
18-22 days (mean=20.2 ± 1.48).  
 
Table 1. Adipose tissue donors’ demographic characteristics, cell 
count, cell viability, cell processing time, and tissue weight 
Age tissue weight (gram) 
Cell culture duration 
(day) 
Cell count 
(/µl) 
Cell viability 
(%) 
60 13.5 18 16000000 95 
40 15 20 9000000 98 
44 17.4 20 12000000 96 
52 16.8 21 10000000 95 
42 23 22 14000000 94 
 
The morphology of ASCs was similar to the 
morphology of bone marrow and umbilical cord blood-
derived MSCs (Figure 1b). 
 
 
Figure 1. (a) Trypan blue staining on homocytometer (magnification: 40x). (b) ASCs morphology assessment by  
light inverted microscopy (magnification: 200x). 
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Characterization of ASCs  
    ASCs were negative for CD11b, 19, 34, 45, HLA-DR, 
and positive for CD105, 44, and CD73 (Figure 2). 
 
Differentiation potential of ASCs 
    We evaluated the differentiation potential of ASC 
isolated by staining with Oil Red O (adipogenic), 
Alizarin Red (osteogenic) (Figure 3). Additionally, 
karyotyping which was performed at a 3th subculture, 
have depicted a normal diploid karyotype (Figure 4). 
 
 
 
 
Figure 2. Cell surface markers of ASCs. Histogram analysis of cell surface markers. ASCs were positive for CD73, CD44, and CD105, and negative 
for CD11b, CD19, CD34, CD45, and HLA-DR. 
 
 
 
Figure 3. Light inverted microscopy photographs of ADSCs induced to differentiate into different lineages. (a) Osteogenic differentiation is 
demonstrated by Alizarin Red staining. (b) An adipogenic differentiation is demonstrated by Oil Red O staining (magnification: 200x). 
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Figure 4. Normal diploid (male) karyotype of adipose-derived mesenchymal stem cells at 3rd subculture. 
 
 
Discussion 
 
Regenerative medicine as an advanced therapy has 
been introduced for treatment of several diseases in 
recent years (6,27). Accordingly, various clinical cell 
transplantation trials are registered at different databases 
including www.clinicaltrials.gov, using MSCs as the 
most common used multipotent stem cells in cellular 
therapies (20). MSCs can be isolated from different 
tissues such as bone marrow, peripheral blood, adipose 
tissue, etc. Recently, advantages of ASCs in 
regenerative medicine are increasingly mentioned. For 
instance, in a published report in 2011, Lindroos et al., 
found 18 clinical trials that used human ASCs in 
regenerative medicine (18). This approach to stem cells 
and advanced cellular therapies seems to be 
accompanied by serious safety concerns (2). 
Accordingly, all steps of cell preparation for clinical 
transplantation must be performed based on appropriate 
standards and protocols such as GMP to achieve a 
reasonable safety and quality (3,23). In this study, we 
tried to demonstrate the feasibility of GMP-compliant 
and clinical grade ASCs preparation according to GMP 
standards. All procedures were performed in our GMP 
facility using relevant protocols and GMP-grade 
materials. ASC products have depicted all known 
characteristics of MSCs, which was reported by 
Dominici et al., (28). In accordance with the current 
state of cellular therapy regulations, all cell products 
should be manufactured adhering to cGMP requirements 
including facility, cGMP compatible or 
clinical grade reagents and materials if they are 
available. If some of them are not available, 
research grade reagents can be used for additional safety 
and quality tests.  Accordingly, clinical and GMP-
grade cell manufacturing cannot be achieved by transferr
ing current basic cell processing methods into a cGMP 
facility (22). A reasonable quality assurance will be 
achieved in cellular therapy when the principles of 
cGMP are considered completely from tissue or cell 
isolation and collection to freezing, storage, and finally 
releasing for transplantation (1). Furthermore, all 
additional reagents must be justified and replaced with 
clinically compatible materials if possible (29,30). One 
of the most important reagents which should be 
considered as a potential risk of transferring 
immunogenic xenoproteins, infectious agents, and 
especially transmissible spongiform encephalopathy 
(TSE) is FBS. In accordance with the European 
Medicines Agency (EMEA) recommendations, its use 
should be avoided when manufacturers have a choice 
from “non-TSE relevant animal species” or non-animal 
origin (6,31). Considering these concerns we used FBS 
pharma grade as an Australian origin and gamma 
irradiated serum which is a high quality FBS that is 
compatible with current regulations and guidelines of 
biopharmaceutical products such as, EMEA guideline 
1793/02 of the committee for proprietary medical 
products (CPMP); EMEA guideline 743/00 of the 
committee for veterinary medical products (CVMP);  the 
Ph. Eur. (European Pharmacopoeia) current edition 
monograph of Bovine Serum (2262); the EU regulation 
2005/567 for Advanced Therapies (AT); and US Code 
of Federal Regulation (9CFR). Additionally, 35 kGy 
effective single box gamma irradiation (for reduction of 
gamma sensitive viruses and mycoplasma) and a broad 
test panel (including mycoplasma, 10 different viruses, 
and Bovine Viral Diarrhea (BVD) antibodies) perform 
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for more safety. For adipose tissue digestion, we used a 
GMP-grade collagenase, which is intended to use in 
clinical cell transplantation. It is compatible with the 
requirements of the EU-Guide to GMP. Furthermore, 
other clinical compatible reagents are commercially 
available. For instance, GMP-grade Ficoll-PaqueTM 
PREMIUM (GE Healthcare Life Sciences, USA), 
TrypLE™  Select  (Invitrogen)  and  TrypZean  (Sigma-
Aldrich) as animal-origin free enzymes (22,32). Besides 
focusing on different reagents and materials that are 
used in clinical cell manufacturing, the manufacturing 
procedures must be designed based on cGMP standards 
to guarantee the safety and quality of cell-based product 
throughout the tissue or cell collection and isolation, 
cryopreservation, banking, releasing, and shipping 
process.  Furthermore, cell manufacturing facility must 
be designed and installed in accordance with the 
relevant standards such as monitoring of air changes and 
its condition, temperature, humidity, airborne particles 
and probable contamination, etc. Likewise, all standard 
operating procedures (SOPs) must be documented (19).  
Translating from the basic stem cell research into 
clinical cell transplantation is a complex process. During 
this translation, avoiding every probable risk and 
achieving a reasonable quality level should be 
considered. Therefore, (stem) cell preparation for the 
clinical application should be performed in accordance 
with cGMP standards. Although use of ASCs for 
treatment of various disorders is increasingly 
recommended by researchers, their clinical application is 
still in its infancy and needs more preclinical and 
clinical studies to demonstrate whether ASCs can meet 
expected scientific values and can be used as a 
successful cellular therapy.  
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